Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
280 SEK | 0.00% | -0.36% | +4.87% |
Sales 2024 * | 24.52B 2.27B | Sales 2025 * | 27.15B 2.51B | Capitalization | 95.16B 8.8B |
---|---|---|---|---|---|
Net income 2024 * | 3.34B 309M | Net income 2025 * | 4.88B 451M | EV / Sales 2024 * | 4.47 x |
Net Debt 2024 * | 14.54B 1.34B | Net Debt 2025 * | 9.22B 852M | EV / Sales 2025 * | 3.84 x |
P/E ratio 2024 * |
28.5
x | P/E ratio 2025 * |
19.6
x | Employees | 1,752 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 50.87% |
Latest transcript on Swedish Orphan Biovitrum AB
1 week | -0.36% | ||
Current month | -1.89% | ||
1 month | +6.22% | ||
3 months | +2.94% | ||
6 months | +20.90% | ||
Current year | +4.87% |
Managers | Title | Age | Since |
---|---|---|---|
Guido Oelkers
CEO | Chief Executive Officer | 59 | 17-05-21 |
Henrik Stenqvist
DFI | Director of Finance/CFO | 57 | 18-07-19 |
Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 68 | 20-12-31 | |
Annette Clancy
CHM | Chairman | 70 | 14-05-07 |
Staffan Schüberg
BRD | Director/Board Member | 55 | 19-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.15% | 233 M€ | +9.07% | ||
0.90% | 5 M€ | +9.66% | ||
0.69% | 148 M€ | +9.14% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 280 | 0.00% | 634,250 |
24-05-02 | 280 | -1.89% | 505,032 |
24-04-30 | 285.4 | +0.71% | 380,444 |
24-04-29 | 283.4 | +0.85% | 451,592 |
24-04-26 | 281 | +0.07% | 1,124,638 |
Delayed Quote Nasdaq Stockholm, May 03, 2024 at 11:29 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.87% | 8.81B | |
-3.79% | 88.14B | |
+1.45% | 40.51B | |
-15.94% | 31.67B | |
+52.66% | 24.62B | |
-14.50% | 15.65B | |
-9.12% | 11.97B | |
-14.38% | 12.07B | |
-42.56% | 11.61B | |
-4.33% | 8.5B |
- Stock Market
- Equities
- SOBI Stock